darifenacin
Selected indexed studies
- Darifenacin. (, 2012) [PMID:31644105]
- Darifenacin: Pharmacology and clinical usage. (Urol Clin North Am, 2006) [PMID:17011383]
- The clinical pharmacokinetics of darifenacin. (Clin Pharmacokinet, 2006) [PMID:16584282]
_Worker-drafted node — pending editorial review._
Connections
darifenacin is a side effect of
Sources
- Darifenacin. (2012) pubmed
- Darifenacin: Pharmacology and clinical usage. (2006) pubmed
- The clinical pharmacokinetics of darifenacin. (2006) pubmed
- Darifenacin: in the treatment of overactive bladder. (2004) pubmed
- Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. (2007) pubmed
- Darifenacin in the treatment of overactive bladder. (2005) pubmed
- Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. (2004) pubmed
- Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. (2004) pubmed
- Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. (2024) pubmed
- Darifenacin Self-assembled Liquid Crystal Cubic Nanoparticles: a Sustained Release Approach for an Overnight Control of Overactive Bladder. (2023) pubmed